Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 2
1992 2
1993 2
1994 5
1995 4
1996 9
1997 10
1998 16
1999 14
2000 13
2001 14
2002 14
2003 16
2004 31
2005 37
2006 41
2007 44
2008 59
2009 64
2010 42
2011 48
2012 43
2013 53
2014 40
2015 51
2016 42
2017 32
2018 34
2019 27
2020 23
2021 21
2022 11
2023 17
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

769 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis.
Furukawa TA, Cipriani A, Cowen PJ, Leucht S, Egger M, Salanti G. Furukawa TA, et al. Lancet Psychiatry. 2019 Jul;6(7):601-609. doi: 10.1016/S2215-0366(19)30217-2. Epub 2019 Jun 6. Lancet Psychiatry. 2019. PMID: 31178367 Free PMC article.
We used a random-effects, dose-response meta-analysis model with flexible splines for SSRIs, venlafaxine, and mirtazapine. FINDINGS: 28 554 records were identified through our search (24 524 published and 4030 unpublished records). 561 published and 121 unpublished full-te …
We used a random-effects, dose-response meta-analysis model with flexible splines for SSRIs, venlafaxine, and mirtazapine. FINDINGS: …
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Brent D, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller M, Vitiello B, Ritz L, Iyengar S, Abebe K, Birmaher B, Ryan N, Kennard B, Hughes C, DeBar L, McCracken J, Strober M, Suddath R, Spirito A, Leonard H, Melhem N, Porta G, Onorato M, Zelazny J. Brent D, et al. JAMA. 2008 Feb 27;299(8):901-913. doi: 10.1001/jama.299.8.901. JAMA. 2008. PMID: 18314433 Free PMC article. Clinical Trial.
INTERVENTIONS: Twelve weeks of: (1) switch to a second, different SSRI (paroxetine, citalopram, or fluoxetine, 20-40 mg); (2) switch to a different SSRI plus cognitive behavioral therapy; (3) switch to venlafaxine (150-225 mg); or (4) switch to venlafaxine plus cogn …
INTERVENTIONS: Twelve weeks of: (1) switch to a second, different SSRI (paroxetine, citalopram, or fluoxetine, 20-40 mg); (2) switch to a di …
Venlafaxine for neuropathic pain in adults.
Gallagher HC, Gallagher RM, Butler M, Buggy DJ, Henman MC. Gallagher HC, et al. Cochrane Database Syst Rev. 2015 Aug 23;2015(8):CD011091. doi: 10.1002/14651858.CD011091.pub2. Cochrane Database Syst Rev. 2015. PMID: 26298465 Free PMC article. Review.
Four of the six studies reported some positive benefit for venlafaxine. In the largest study by Rowbotham, 2004, 56% of participants receiving venlafaxine 150 to 225 mg achieved at least a 50% reduction in pain intensity versus 34% of participants in the placebo gro …
Four of the six studies reported some positive benefit for venlafaxine. In the largest study by Rowbotham, 2004, 56% of participants …
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Kishi T, Ikuta T, Sakuma K, Okuya M, Hatano M, Matsuda Y, Iwata N. Kishi T, et al. Mol Psychiatry. 2023 Jan;28(1):402-409. doi: 10.1038/s41380-022-01824-z. Epub 2022 Oct 17. Mol Psychiatry. 2023. PMID: 36253442 Free PMC article.
Compared to placebo, venlafaxine was associated with a lower incidence of dizziness, while desvenlafaxine, sertraline, and vortioxetine were associated with a higher incidence of nausea/vomiting. In conclusion, desvenlafaxine, paroxetine, venlafaxine, and vortioxeti …
Compared to placebo, venlafaxine was associated with a lower incidence of dizziness, while desvenlafaxine, sertraline, and vortioxeti …
Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis.
Ramaswami R, Villarreal MD, Pitta DM, Carpenter JS, Stebbing J, Kalesan B. Ramaswami R, et al. Breast Cancer Res Treat. 2015 Jul;152(2):231-7. doi: 10.1007/s10549-015-3465-5. Epub 2015 Jun 12. Breast Cancer Res Treat. 2015. PMID: 26067931 Review.
We searched Medline, Scopus, and Cochrane Central Register of Controlled Trials from inception till May 2015 for venlafaxine (75 mg once daily or greater) with non-hormonal comparators for the treatment of hot flashes in female breast cancer patients. ...Asymmetry in the c …
We searched Medline, Scopus, and Cochrane Central Register of Controlled Trials from inception till May 2015 for venlafaxine (75 mg o …
Dose-response relationship with venlafaxine.
Kelsey JE. Kelsey JE. J Clin Psychopharmacol. 1996 Jun;16(3 Suppl 2):21S-26S; discussion 26S-28S. doi: 10.1097/00004714-199606002-00005. J Clin Psychopharmacol. 1996. PMID: 8784645 Review.
Considerations when selecting a first-line antidepressant agent include the potential for achieving greater response with increasing dosages, thereby allowing greater flexibility in dosing. The efficacy and dose-response of venlafaxine, a novel serotonin and norepinephrine …
Considerations when selecting a first-line antidepressant agent include the potential for achieving greater response with increasing dosages …
Efficacy of venlafaxine compared with tricyclic antidepressants in depressive disorder: a meta-analysis.
van den Broek WW, Mulder PG, van Os E, Birkenhäger TK, Pluijms E, Bruijn JA. van den Broek WW, et al. J Psychopharmacol. 2009 Aug;23(6):708-13. doi: 10.1177/0269881108089821. Epub 2008 Jun 18. J Psychopharmacol. 2009. PMID: 18562424 Review.
With respect to the pharmacological characteristic, venlafaxine is comparable with tricyclic antidepressants (TCAs), and venlafaxine might be comparable in efficacy. ...The odds ratios were not homogenous across studies (P = 0.0213). The average dose of venlafaxi
With respect to the pharmacological characteristic, venlafaxine is comparable with tricyclic antidepressants (TCAs), and venlafaxi
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, Mazzucco C, Hough D, Thase ME, Shelton RC, Molero P, Vieta E, Bajbouj M, Manji H, Drevets WC, Singh JB. Popova V, et al. Am J Psychiatry. 2019 Jun 1;176(6):428-438. doi: 10.1176/appi.ajp.2019.19020172. Epub 2019 May 21. Am J Psychiatry. 2019. PMID: 31109201 Clinical Trial.
Venlafaxine can reduce the migraine attacks as well as amitriptyline: A noninferiority randomized trial.
Hedayat M, Nazarbaghi S, Heidari M, Sharifi H. Hedayat M, et al. Clin Neurol Neurosurg. 2022 Mar;214:107151. doi: 10.1016/j.clineuro.2022.107151. Epub 2022 Jan 29. Clin Neurol Neurosurg. 2022. PMID: 35151971 Clinical Trial.
The first group received amitriptyline at a dose of 25 mg every night, and the second group received venlafaxine at a dose of 37.5 mg daily. The duration of treatment was eight weeks. ...In terms of adverse drug reactions, patients in the amitriptyline group complained mor …
The first group received amitriptyline at a dose of 25 mg every night, and the second group received venlafaxine at a dose of 37.5 mg …
Clinical evaluation of venlafaxine.
Ballenger JC. Ballenger JC. J Clin Psychopharmacol. 1996 Jun;16(3 Suppl 2):29S-35S; discussion 35S-36S. doi: 10.1097/00004714-199606002-00007. J Clin Psychopharmacol. 1996. PMID: 8784646 Review.
Recent studies have shown venlafaxine to be an effective first-line agent for patients who have depression of varying severity. ...Demographics and baseline scores were similar among study patients in each trial. In both trials, venlafaxine was significantly more ef …
Recent studies have shown venlafaxine to be an effective first-line agent for patients who have depression of varying severity. ...De …
769 results